Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

1.

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2011 Jan 15;203(2):246-57. doi: 10.1093/infdis/jiq043. Epub 2010 Dec 9.

PMID:
21288825
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.

Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group.

HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x. Epub 2009 Sep 1.

PMID:
19732176
[PubMed - indexed for MEDLINE]
3.

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.

Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

BMC Infect Dis. 2012 Nov 12;12:296. doi: 10.1186/1471-2334-12-296.

PMID:
23145925
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M.

AIDS. 2000 Mar 31;14(5):499-507.

PMID:
10780712
[PubMed - indexed for MEDLINE]
5.

Gender differences in discontinuation of antiretroviral treatment regimens.

Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):336-41. doi: 10.1097/QAI.0b013e3181b628be.

PMID:
19654551
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E.

PLoS One. 2011;6(12):e27810. doi: 10.1371/journal.pone.0027810. Epub 2011 Dec 6.

PMID:
22162992
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C.

BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38.

PMID:
22333484
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
[PubMed - indexed for MEDLINE]
9.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.

Int J Antimicrob Agents. 2005 Jul;26(1):88-91.

PMID:
15878262
[PubMed - indexed for MEDLINE]
10.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES.

Clin Infect Dis. 2011 Jul 15;53(2):185-96. doi: 10.1093/cid/cir324.

PMID:
21690627
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
[PubMed - indexed for MEDLINE]
12.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
[PubMed - indexed for MEDLINE]
13.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2010 Apr;20(4):217-30. doi: 10.1097/FPC.0b013e328336eee4.

PMID:
20139798
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

Zhu L, Liao S, Child M, Zhang J, Persson A, Sevinsky H, Eley T, Xu X, Krystal M, Farajallah A, McGrath D, Molina JM, Bertz R.

J Antimicrob Chemother. 2012 Feb;67(2):465-8. doi: 10.1093/jac/dkr490. Epub 2011 Nov 25.

PMID:
22121190
[PubMed - indexed for MEDLINE]
Free Article
15.

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.

PMID:
19731418
[PubMed - indexed for MEDLINE]
16.

Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

Crane HM, Van Rompaey SE, Kitahata MM.

AIDS Patient Care STDS. 2007 Dec;21(12):920-9.

PMID:
18154489
[PubMed - indexed for MEDLINE]
17.

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort.

Yuan Y, L'italien G, Mukherjee J, Iloeje UH.

HIV Med. 2006 Apr;7(3):156-62.

PMID:
16494629
[PubMed - indexed for MEDLINE]
18.

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

Clin Infect Dis. 2012 Nov;55(9):1262-9. doi: 10.1093/cid/cis621. Epub 2012 Jul 19.

PMID:
22820542
[PubMed - indexed for MEDLINE]
Free Article
19.

Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study.

Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, Calmy A, Bernasconi E, Vernazza P, Weber R, Bucher HC, Battegay M, Fehr J.

J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):472-8. doi: 10.1097/QAI.0b013e3182a61ea9.

PMID:
23892243
[PubMed - indexed for MEDLINE]
20.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk